Fatores precipitantes na porfiria cutânea tardia no Brasil com ênfase\ud
nas mutações do gene (HFE) da hemocromatose. Estudo de 60 casos by Vieira, Fatima Mendonça Jorge et al.
An Bras Dermatol. 2013;88(4):530-40.
▲
Precipitating factors of porphyria cutanea tarda in Brazil with
emphasis on hemochromatosis gene (HFE) mutations. 
Study of 60 patients*
Fatores precipitantes na porfiria cutânea tardia no Brasil com ênfase 
nas mutações do gene (HFE) da hemocromatose. Estudo de 60 casos
Fatima Mendonça Jorge Vieira1 Maria Cristina Nakhle2 Clarice Pires Abrantes-Lemos3
Eduardo Luiz Rachid Cançado4 Vitor Manoel Silva dos Reis5
DOI: http://dx.doi.org/10.1590/abd1806-4841.20132048
Abstract: BACKGROUND: Porphyria cutanea tarda is the most common form of porphyria, characterized by the decreased activity of the uroporphyrinogen
decarboxylase enzyme. Several reports associated HFE gene mutations of hereditary hemochromatosis with porphyria cutanea tarda worldwide, although up
to date only one study has been conducted in Brazil. 
OBJECTIVES: Investigation of porphyria cutanea tarda association with C282Y and H63D mutations in the HFE gene. Identification of precipitating factors
(hepatitis C, HIV, alcoholism and estrogen) and their link with HFE mutations. 
METHODS: An ambispective study of 60 patients with PCT was conducted during the period from 2003 to 2012. Serological tests for hepatitis C and HIV were
performed and histories of alcohol abuse and estrogen intake were investigated. HFE mutations were identified with real-time PCR. 
RESULTS: Porphyria cutanea tarda predominated in males and alcohol abuse was the main precipitating factor. Estrogen intake was the sole precipitating fac-
tor present in 25% of female patients. Hepatitis C was present in 41.7%. All HIV-positive patients (15.3%) had a history of alcohol abuse. Allele frequency for
HFE mutations, i.e., C282Y (p = 0.0001) and H63D (p = 0.0004), were significantly higher in porphyria cutanea tarda patients, compared to control group. HFE
mutations had no association with the other precipitating factors. 
CONCLUSIONS: Alcohol abuse, hepatitis C and estrogen intake are prevalent precipitating factors in our porphyria cutanea tarda population; however, hemochro-
matosis in itself can also contribute to the outbreak of porphyria cutanea tarda, which makes the research for HFE mutations necessary in these patients
Keywords: Hemochromatosis; Hepatitis; Iron overload; Mutation; Porphyria cutanea tarda
Resumo: FUNDAMENTOS: A porfiria cutânea tardia é a forma mais comum das porfirias e caracteriza-se pela diminuição da atividade da enzima uropor-
firinogênio descarboxilase. Há vários relatos da associação das mutações do gene HFE da hemocromatose hereditária com porfiria cutânea tardia no mundo,
mas até hoje apenas um estudo foi realizado no Brasil. 
OBJETIVOS: Estudar a associação da porfiria cutânea tardia com as mutações C282Y e H63D do gene HFE. Identificar os fatores precipitantes (hepatite C, HIV,
etilismo e estrógeno) e sua relação com as mutações HFE. 
MÉTODOS: Estudo ambispectivo de 60 pacientes com porfiria cutânea tardia no período de 2003 a 2012. Investigou-se as sorologias para hepatite C, anti-HIV,
histórico de etilismo e ingestão de estrógenos. As mutações HFE foram identificadas com PCR em tempo real. 
RESULTADOS: A porfiria cutânea tardia predominou no sexo masculino e o etilismo foi o principal fator precipitante. A ingestão de estrógenos foi o único fator
precipitante em 25% das mulheres. A hepatite C estava presente em 41,7%. Todos os pacientes com HIV (15,3%) apresentavam etilismo associado. A frequên-
cia dos alelos C282Y (p=0,0001) e H63D (p=0,0004) do gene HFE foi significativamente mais elevada nos pacientes com porfiria cutânea tardia em relação à
população controle. As mutações HFE não apresentavam associação com os demais fatores precipitantes. 
CONCLUSÕES: Etilismo, hepatite C e ingestão de estrógenos (em mulheres) são fatores precipitantes prevalentes na nossa população com porfiria cutânea tar-
dia, entretanto a hemocromatose isoladamente também pode contribuir para o desencadeamento da porfiria cutânea tardia, o que torna a pesquisa das
mutações HFE necessária nestes pacientes.
Palavras-chave: Hemocromatose; Hepatite; Mutação; Porfiria cutânea tardia; Sobrecarga de ferro
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for most cases of hereditary hemochromatosis (HH)
“type I” (88% of 178 HH patients in the study).13
Several literature studies exist which describe
increased frequency of HFE gene mutations in
patients with PCT (Chart 1). On chart 1 we computed
the frequencies of C282Y and H63D alleles in PCT
patients as well as control populations of different
countries, calculating p-value. C282Y mutation origi-
nated in the population of Northwestern Europe
(Celts, Vikings or Germans) and its worldwide distri-
bution reflects migration of these populations, i.e.,
higher incidence occurs among Caucasians in
Northwestern Europe, Canada, USA, Australia, New
Zealand and South Africa.14 These mutations are rare
among Asian populations, Pacific Islanders, indige-
nous Australians, Africans and South Americans.15 In
Chile the frequency of HFE mutations in patients suf-
fering from PCT was not different from the control
group.16 In Germany and USA the frequency of C282Y
and H63D mutations is higher in patients suffering
from PCT, compared to control population.11,17,18
However, in one of the studies conducted in Germany
no difference was observed in the frequency of H63D
mutation.18 France and Portugal presented a greater
frequency of C282Y mutation in the normal popula-
tion in the North rather than in the South, probably
due to the increased influence of Celtic origin in the
North.19,20 The role of S65C mutation does not appear
to be decisive in PCT, as studies demonstrate that
prevalence was no different between patients suffer-
ing from PCT and the control group.20 In the United
Kingdom, Australia and São Paulo, Brazil, the C282Y
mutation frequency was higher in PCT patients com-
pared to controls, and no difference was observed in
H63D mutation.21,22,23 Association between H63D
mutation and PCT has been described in studies in the
Mediterranean region. France, Spain, Italy, and Brazil
showed a high frequency of H63D mutation in their
populations.20,23,24,25 In Spain there was a significant
association of the two mutations only in sporadic PCT
and not in the familial form.25
The ‘major’ mutation is caused by a guanine to
adenine transition at nucleotide 845 of the HFE gene
(845G � A), which leads to  replacement of cysteine by
tyrosine at amino acid position 282 in the HFE protein,
currently called ‘C282Y’ mutation. The ‘minor’ muta-
tion is a replacement of cytosine by guanine at
nucleotide 187 of the HFE gene (187C�G), resulting in
replacement of histidine by aspartic acid in amino acid
position 63 of HFE protein, named ‘H63D’ mutation.26
The C282Y mutation abolishes HFE protein
interaction with transferrin receptor (TfR), which may
be enough to cause an iron deposition overload.27
Now mutation H63D induces a functional change,
INTRODUCTION
Porphyria cutanea tarda (PCT) is the most com-
mon form of porphyria, characterized by decreased
activity of uroporphyrinogen decarboxylase (UROD)
enzyme and consequent accumulation of uropor-
phyrins and hepta-carboxyl porphyrinogens, predomi-
nantly in the liver.1 Clinically it is characterized by skin
fragility, hyperpigmentation and blistering affecting
photo exposed areas, facial hypertrichosis and labora-
tory exams indicating iron overload and increased lev-
els of liver enzymes.2 Diagnosis is based upon clinical
manifestations, dosage of 24-hour urinary porphyrins
(URO/COPRO > 3:1) and increased fecal levels of iso-
coproporphyrins (ISOCOPRO) or increase in plasma
porphyrins in anuric patients.2 PCT can be induced by
several precipitating factors: alcoholism, estrogens,
viral infections, conditions which lead to iron overload
(hereditary hemochromatosis, hemodialysis, etc.) and
exposure to polyhalogenated aromatic hydrocarbons
triggering toxic PCT. Most patients present multiple
precipitating factors. Individuals suffering from PCT
are apparently genetically predisposed to developing
UROD deficiency in response to liver damage.3 Iron
acts as a switch that controls the generation of UROD
inhibitors, commencing a vicious cycle of UROD inac-
tivation; its removal allows restoration of UROD activ-
ity.4 Remission after phlebotomy and treatment failure
when iron supplement is administered, suggests that
iron has an important role in the pathogenesis of the
disease.5,6 Interaction occurs between hereditary and
acquired factors implied in UROD inactivation; howev-
er, these interactions remain undefined.7
As alcohol consumption is associated with iron
overload, several studies encountered an association
with HFE mutations.8 The pathogenic role of hepatitis
C virus (HCV) in triggering PCT has been reported
since 1992 and a meta-analysis of 50 studies was per-
formed by Gisbert et al.9 The calculated average of HCV
prevalence was 47% and varied depending on the
country and type of PCT (57% in sporadic PCT and
26% in familial PCT).9 Association of PCT with human
immunodeficiency virus (HIV) infections has been sug-
gested; however, most of these patients have other pre-
cipitating factors, such as alcoholism, iron overload and
co-infection by HCV.10 Estrogen is an independent pre-
cipitating factor for the development of PCT; no hepat-
ic siderosis was identified in these patients.11 There is a
genetic predisposition to PCT in these patients, as 84%
have decreased UROD activity, approximately 50% of
normal value.3 PCT can occur in patients with chronic
renal failure (CRF) undergoing hemodialysis, by preex-
isting decrease of hepatic UROD activity.12
In 1996, Feder et al. encountered two missense
mutations, C282Y and H63D, in the HFE gene located
on p21.3 region of chromosome 6p, which accounts
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which leads to a loss of ability to reduce affinity of TfR
to transferrin.27 Regardless of the exact mechanism,
adults with HH type 1 present a gradual increase in
total body iron with increased transferrin saturation
(Tsat) and serum ferritin, resulting in abnormal iron
deposition, predominantly in hepatocytes but also
affecting other organs. The more pronounced clinical
manifestations are related to C282Y mutation and
milder ones are related to H63D and S65C mutations.14
Absence of mutations is named wild type (WT).
C282Y/WT, H63D/WT and H63D/H63D genotypes
are not associated with phenotypic manifestation of
the disease, although they present a small elevation of
iron saturation.28
Currently, the presence of homozygosis for
C282Y, associated with evidence of iron overload,
such as increase in concentration of hepatic iron,
increase of transferrin saturation (Tsat) and ferritin
levels are the gold standard for a definitive diagnosis
of HH.29 Gene expression (penetrance) is highly vari-
able; not all homozygotes for C282Y will develop iron
overload or HH. It is estimated that 40.0% to 70.0% of
homozygous individuals for C282Y will develop
some laboratory evidence of iron overload without
clinical complications and that at least 50.0% of males
and 25.0% of females with this genotype will develop
clinical complications, secondary to iron overload.30
One to 11.0% of compound heterozygotes will bring
about clinical HH.31 Apparently there are gene modi-
fiers that regulate the manifestation of HFE muta-
tions, which when combined with individual differ-
ences of iron loss (such as females who menstruate),
result in a considerable variation in clinical manifesta-
tions of risk genotypes (C282Y/C282Y and
C282Y/H63D).14 In H63D homozygotes, 80.0% are
clinically normal and 20.0% will develop iron over-
load, which is almost twice the percentage found in
individuals with WT/WT genotype; H63D mutation
is associated with a milder form of HH.32 The clinical
symptoms of HH occur after the third decade of life,
because iron deposition is gradual and cumulative.
Iron build-up occurs in the liver (leading to cirrhosis
and increased risk of hepatocellular carcinoma
(HCC)), pancreas (diabetes mellitus), heart (heart fail-
ure and arrhythmia), osteoarticular system (arthralgia
and osteoporosis) and pituitary gland (hypothy-
roidism, hypogonadism). Type II diabetes, joint pain
and muscle fatigue are frequent manifestations.33
Most patients suffering from PCT present
increased levels of serum iron and ferritin, so these
changed parameters are not used to diagnose HH in
these patients.34,35 In addition, ferritin can be increased
in alcoholics and in viral infections (HCV and HIV)
associated with PCT. Several authors discovered larg-
CHART 1: Allele frequency of C282Y and H63D mutations in control population and in porphyria cutanea 
tarda patients in different countries
STUDY Country Allele frequency in Allele frequency p- value*
Author / Year control population (%) in PCT (%)
Nr. C282Y H63D Nr. C282Y H63D
Tannapfel, 200117
Frank, 200618
Brady, 200021
Stuart, 199822
Bulaj, 200011
Chiavérini, 200320
Enriquez de
Salamanca, 199925
Sampietro, 199824
Martinelli, 200023
Wolff, 200616
Germany
Germany
United Kingdom
Australia
USA
Southern France
Spain
Northern Italy
São Paulo (Brazil)
Chile
115 1.3 5.2
54 3 19
10566 8.2 15.3
Outros 
estudos
56 6.2 10.7
58 0.9 12.9
50 2 18
128 0.7 12.9
278 4 31.1
178 (H63D) 1.2 12.4
/82 (C282Y)
190 30.3 27.9
51 16 22
84 36.9 14.9
27 27.8 25.9
87 30.5 17.8
33 9 30.3
69 PCTs 10.8 32.6
19 PCTf 7.9 15.8
68 2.2 29.4
23 10.8 21.7
20 7.5 20
C282Y e H63D; p < 0.0001
C282Y, p < 0.0013; H63D p=0.6083
C282Y, p<0.0001; H63D, p=1.0000
p < 0.001 for C282Y/C282Y and C282Y/H63D.
Used control population of other studies.
C282Y, p<0.0001; H63D, p=0.1271
C282Y, p=<0.0097; H63D, p=0.0060
PCTs - C282Y p=0.0095; H63D p=0.0119
PCTf - C282Y p=0.1281; H63D p=1.0000
C282Y, p=0.3464; H63D, p=0.0001
C282Y, p=0.02; H63D, p=1.0000 
C282Y, p=0.0527; H63D, p=0.2128
Note: * Our calculation of p-value, considering allele frequency in each study; Nr. = Number of patients; PCTs = sporadic porphyria cutanea tarda;
PCTf = familial porphyria cutanea tarda
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er parameters of iron levels in patients suffering from
PCT, as well as C282Y homozygotes or C282Y/H63D
compound heterozygotes.11 However, a German study
with 190 cases of PCT demonstrated that there is no
difference between serum iron, liver iron, transferrin
saturation and liver enzymes in patients, with or
without HFE gene mutations.17 Bulaj et al. did not
observe a significant difference between the frequen-
cy of HCV in PCT patients with HFE mutations and
those with wild type alleles (WT), suggesting that
HFE mutations do not predispose them to HCV infec-
tion.11 Sampietro et al. in Northern Italy observed that
there was an increase in the prevalence of H63D
mutation, although this mutation was not linked to
the iron status.24 As HCV is frequent in Italian patients
suffering from PCT and rare in PCT patients of
Northern Europe, Sampietro et al. examined a control
group with active hepatitis C and without PCT, in
order to discard a possible association between H63D
mutation and HCV infection. Prevalence of HFE
mutations in this group was identical to that observed
in control groups, suggesting that the increased
prevalence of H63D was in fact associated with PCT.24
The role of H63D mutation in hemochromatosis has
not yet been clarified, as it is rare in classical
hemochromatosis and frequent in normal individuals.
Some authors suggest that H63D could be a polymor-
phic marker of another unknown HFE mutation.24
The aims of this study cover examination of
PCT association with C282Y and H63D mutations of
HFE gene in Brazilian patients and identification of
associated precipitating factors (alcoholism, hepatitis
C, HIV infection and ingestion of estrogens), as well
as their relation with presence or absence of HFE
mutations.
MATERIALS E METHODS
Patients
Sixty patients were included in the study, dur-
ing the period from 2003 to 2011. Ethnicities consid-
ered were: Euro-Brazilian, African Brazilian, Asian
Brazilian and mixed ethnicities. The comorbidities
were alcoholism, estrogen intake and virus infections
(HCV and HIV). We included in the clinical history
exposure to chlorinated hydrocarbons and similar
clinical manifestations in the family. All patients
signed a free and informed consent term approved by
the Committee for Research Projects Analysis of the
Hospital and had blood collected for research of
hemochromatosis gene mutations (C282Y and H63D).
The frequency of alleles of C282Y and H63D muta-
tions in patients with PCT was compared with fre-
quency of alleles obtained from another study carried
out in the same hospital in São Paulo (HCFMUSP),
with 395 blood donors, by Pereira et al. in 2001.36
Method
PCT diagnosis was based on clinical features
and quantification of urinary porphyrins (by High
Performance Liquid Chromatography – HPLC) in
urine sample collected for 24 hours using
URO:COPRO >3:1 ratio. Liver enzymes [alanine
transaminase (ALT), aspartate transaminase (AST),
gamma-glutamyl transpeptidase (GGT)] and iron pro-
file (transferrin saturation (Tsat), serum iron, ferritin,
and iron binding capacity) were requested.
Biochemical iron overload and liver enzyme increase
were taken into consideration when values recorded
were above the upper limit of normal (ULN) levels in
reference values established by the Central
Laboratory Division routine.
The genomic DNA leukocyte was extracted by
a modified Chomczynski and Sacchi method.37 The
final quantification of DNA concentration was
obtained by Nanodrop™ ND-1000 Spectrophotometer
reading, by 260 nm ultraviolet light absorbance and
degree of DNA purity, which was evaluated and
determined by ratio of 260/A280 nm. DNA whose
ratio was ≥ 1.8 were used. DNA samples were stored
in refrigerator at 2-8ºC to be used in amplification
reactions. C282Y and H63D mutation research was
carried out by the real-time polymerase chain reaction
(PCR-RT) technique, using 7300 Real Time PCR
System ABI PRISM™ (APPLIED Ecosystem, USA). We
used the detection system: Tammany® SNP Geno typ-
ing Assays (Applied Microsystems, USA), in which
primers and probes labeled with fluorescent sub-
stances, in our case FAM™ and VIC
®
, paired in the tar-
get DNA region, allowing the identification of differ-
ent alleles.
The study had an perspective and not direction-
al outline. Data were obtained in a longitudinal form.
Measures were applied in order to analyze frequency
of each genotype, as well as of C282Y and H63D alle-
les of HFE gene of hereditary hemochromatosis (HH)
in 60 patients with PCT, at 95% confidence intervals,
separating the following variables (precipitating fac-
tors): alcoholism, hepatitis C virus (HCV), human
immunodeficiency virus (HIV), and estrogen intake.
We verified if there was an association between muta-
tions (C282Y and H63D) and the variables listed
above using Fisher’s Exact Test. The adopted signifi-
cance level was 5% (p<0.05). We analyzed the relation
of HFE genotype with iron profile (serum iron, fer-
ritin, transferrin saturation) and liver enzymes (AST,
ALT and GGT). 
RESULTS
PCT predominated in males (73.3%) and there
was no difference regarding the age at which the dis-
ease began in males and females (average 44.7 years).
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GRAPH 1: Distribution of coexisting precipitating factors  
The genotype did not interfere in age of onset of PCT.
Mixed ethnicities were prevalent in most patients
(72%) and the other ethnic groups were: Euro-
Brazilian (23%), African Brazilian (3%) and Asian
Brazilian (2%). The precipitating factors considered
were: alcoholism, hepatitis C virus (HCV), estrogen
intake, family history of PCT and diagnosis of hered-
itary hemochromatosis (HH) (considering clinical
manifestation and/or presence of C282Y/C282Y or
C282Y/H63D mutations). The majority of patients
(63%) presented two or more coexisting precipitating
factors. Graph 1 shows the distribution of number of
precipitating factors coexisting in the population of 60
patients and these factors are described in table 1.
Chronic alcoholism was present in 71.7% (43 of
60 patients) and 48.8% (21 of 43) of these had HCV.
Social alcoholism was referred by 10 of 60 patients
(16.7%). Anti-CV was positive in 4l.7% (25 of 60
patients); 84% of these (21 of 25) were alcoholics and
20% (5 of 25) also presented positive anti-HIV. As for
the HCV genotype, only nine patients were found to
have it: two with genotype ‘1a’, four with ‘1b’ and
three with ‘3a’. Anti-HIV was positive in 15.3% (9 of
59 patients); all patients had chronic alcoholism and
five of these also presented positive anti-CV. 
Only PCT family history was investigated; it was
not possible to determine dosage of UROD enzyme
activity in erythrocytes or search for UROD mutations
in these patients. PCT case histories in the family were
present in 28.3% (17 of 60 patients). Among these cases:
17.6% (3 of 17) presented this factor as the main precip-
itating factor; 58.8% (10 of 17) were alcoholics, 17.6% (3
of 17)  hereditary hemochromatosis and 23.5% (4 of 17)
estrogen intake. All cases with a PCT family history
were negative for hepatitis C.
Considering 16 women in this study separately,
in 50% (8 of 16) PCT was triggered by estrogens, this
Precipitating Factors Nº Patients % Patients
Alcoholism + HCV 16 26.7%
Alcoholism 9 15.0%
Alcoholism + FH 7 11.7%
Alcoholism + HCV + HIV 5 8.3%
HCV 4 6.7%
Estrogens 4 6.7%
Alcoholism + HIV 3 5.0%
Family history of PCT (FH) 3 5.0%
FH + HH 2 3.3%
Alcoholism + Estrogens + FH 2 3.3%
Alcoholism + HIV + FH 1 1.7%
Estrogens + FH 1 1.7%
Estrogens + FH + HH 1 1.7%
Hereditary Hemochromatosis (HH) 1 1.7%
Social Alcoholism 1 1.7%
TOTAL 60 100.0%
TABLE 1: Association of precipitating factors in 60
patients suffering from porphyria cutanea tarda
Note: HCV = Positive Serology for hepatitis C virus; FH = Family
History of PCT; HIV = Positive Serology for HIV virus; HH =
Hereditary Hemochromatosis (C282Y/C282Y or C282Y/H63D genoty-
pes ou HH clinical phenotype).
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60
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being the main precipitating factor in four patients. As
for the other four patients with PCT triggered by
estrogen: one presented PCT family history, one had
compound heterozygosity for HFE mutation
(C282Y/H63D) and two had  associated chronic alco-
holism and family history. Still among females, in 25%
(4 of 16) hepatitis C was the precipitating factor, and
three of these mentioned social alcoholism. One of the
females presented a previous phenotypic diagnosis of
HH, which was the only precipitating factor in this
patient. PCT family history was present in 31.25% (5
of 16  females), of these one featured family history as
the only precipitating factor and another one featured
only HFE mutation (C282Y/H63D genotype) without
other precipitating factors. One female presented only
social alcoholism. 
The respective frequencies and confidence
intervals for each precipitating factor or associated
disease are described in table 2. Regarding associated
diseases, two male patients were diagnosed with
hepatocellular carcinoma (HCC). The first one was 60
years of age and developed HCC 32 years after onset
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of disease; he presented several relapses as a conse-
quence of not stopping alcohol consumption, and
alcoholism and HCV were the precipitating factors.
The second patient was diagnosed with HCC at 56
years of age, 15 years after onset of disease and pre-
sented the same precipitating factors as the previous-
ly described patient. Diabetes mellitus was present in
15% (9 of 60 patients) and one of the patients had prior
clinical diagnosis of hemochromatosis. The other
three patients with hemochromatosis genotype (one
C282Y/C282Y and two C282Y/H63D) did not present
diabetes.
Research of C282Y and H63D mutations in HFE
gene for HH was carried out on 60 patients. The most
frequent genotype was the wild type (WT/WT),
found in 25 patients (41.7%). The frequency of each
genotype is described in table 3.
In our study, frequency of the C282Y allele was
8.3% and frequency of the H63D allele was 27.5%. In
order to compare these findings with a control group,
a study was conducted with 395 normal people who
were recruited from the Blood Bank of the same
Hospital (HCFMUSP), to obtain allele frequency in
controls (Table 3). Allele frequency was significantly
higher in PCT patients in relation to the control group
for C282Y (8.3% vs. 1.77%; odds ratio 5.02; IC [95%] =
[4.1%; 14.8%], p = 0.0001], p = 0.0001) and H63D
(27.5% vs. 14.05%; odds ratio 2.32; IC [95%] = [19.7%;
36.4%], p= 0.0004). 
Phenotypic or clinical manifestation of
hemochromatosis was the only precipitating factor in
the patient, who presented prior clinical diagnosis of
HH despite heterozygous genotype for H63D. Two
brothers had HH diagnosis only after research of HFE
mutations (a C282Y/C282Y male and a C282Y/H63D
female). Another compound heterozygous patient
(C282Y/H63D) is being monitored, in order to
observe if clinical signs of hemochromatosis are pres-
ent. 
Precipitating factors were related to serology
for hepatitis C and there was no association with alco-
holism, estrogens, HIV, HFE mutations or HH (Table
4). The only association (p < 0.05) that occurred was
that none of the cases had a family history within the
HCV group. 
As we analyzed if precipitating factors (HCV,
HIV, alcoholism and estrogen) were associated with
presence of alleles, no association was observed with
C282Y or H63D alleles (Table 5). Patients with dia-
betes mellitus tended to have a higher frequency of
H63D allele than patients without diabetes (44.4% vs.
23.5%; p-value = 0.0834; as for C282Y allele no such
difference occurred. Patients with PCT family history
had a tendency to an increased frequency of C282Y
and H63D alleles, but it was not statistically signifi-
cant (p=0.1440 for C282Y; p=0.2514 for H63D). 
In table 6, as biochemical parameters of patients
with and without HCV were compared, it was
observed: 1. Iron levels were lower in HCV patients,
but this was not statistically significant; 2. Liver
enzymes were higher in HCV patients (p < 0.05).
Biochemical parameters were also distributed
according to genotype in table 7. It was observed that
Mutations Nr. of Patients % Patients
Genotype
C282Y / WT 6 10
C282Y / C282Y 1 1.7
H63D / WT 21 35
H63D / H63D 5 8.3
C282Y / H63D 2 3.3
WT / WT 25 41.7
Total of patients 60 100
Alleles in PCT
C282Y 10/120 alleles 8.3
H63D 33/120 alleles 27.5
Alleles in Control Population
C282Y 14/790 alleles 1.77%
H63D 111/790 alleles 14.05%
TABLE 3: Frequency of each genotype and of C282Y
and H63D alleles in 60 patients suffering from porp-
hyria cutanea tarda and in 395 individuals of control
population
Note: WT = Wild Type
Alcoholism 43 71.70% 58.60% 82,50%
Hepatitis C - HCV 25 41.70% 29.10% 55,10%
Family history 17 28.33% 17.45% 41,44%
HIV 9 15.30% 7.20% 27,00%
Diabetes mellitus 9 15.00% 7.10% 26,60%
Estrogen (only ♀)1 8 50.00% 24.70% 75,30%
Hereditary Hemochromatosis2 4 6.67% 1.85% 16,20%
Hepatocellular Carcinoma 2 3.33% 0.41% 11,53%
Precipitating factor 
or associated disease
Nr. Estimate
CI (95%)
Lower limit Upper limit
TABLE 2: Frequency of each precipitating factor or
associated disease and its confidence interval
Note: ♀: female; CI: Confidence interval; 1 Group is composed of 16
female patients; 2 Patients possessing clinical manifestation of here-
ditary hemochromatosis or HFE gene mutation (C282Y/C282Y or
H63D/C282Y genotype).
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Alcoholism 60 43 (71.7%) 21 (84.00%) 22 (62.85%) 0.0886
Estrogen ♀ 16 8 (50%) 0 (0%) 8 (66.67%) 0.0769
Hepatitis C - HCV 60 25 (41.70%) --- 
HIV 59 9 (15.25%) 5 (20.83%) 4 (11.43%) 0.464
FH 60 17 (28.3%) 0 (0%) 17 (48.57%) <0.0001
Risk for HH1 60 4 (6.67%) 0 (0%) 4 (11.42%) 0.1333
HFE Mutations2 60 35 (58.3%) 13 (52%) 22 (62.85%) 0.4365
C282Y3,4 60 9 (15%) 3 (12%) 6 (17.14%) 0.7222
H63D3,4 60 28 (46.7%) 10 (40%) 18 (51.42%) 0.4386
Precipitating
Factors
Nr.
Patients
tested
Patients 
with the 
precipitating
factor
Patients 
with HCV 
Nr. = 25
Patients
negative for
HCV 
Nr. = 35
p-value
TABLE 4: Precipitating factors related to positive or
negative serology for hepatitis C (HCV) 
Note: Nr.: number of tested patients; 
♀: female; 
HCV: hepatitis C virus; 
HIV: human immunodeficiency virus; 
FH: PCT family history; 
HH: hereditary hemochromatosis. 
1 Phenotypic manifestation of patients with hemochromatosis (HH)
or genotype with greater risk of HH (C282Y/H63D and
C282Y/C282Y; 
2 Total number of patients with at least one of alleles (C282Y and
H63D); 
3 Present at least one C282Y and H63D mutation allele; 
4 Compound heterozygotes entering C282Y and H63D patients.
HCV With 6.0% 0.5189 22.0% 0.4042
Without 10.0% 30.0%
HIV With 5.5% >0.9999 11.1% 0.1487
Without 8.8% 30.0%
Alcoholism With 6.9% 0.4665 22.1% 0.1074
Without 11.8% 38.2%
Estrogen With 6.3% >0.9999 43.8% >0.9999
Without 6.3% 43.8%
Diabetes With 5.6% >0.9999 44.4% 0.0834
Without 8.8% 23.5%
FH With 14.7% 0.1440 35.3% 0.2514
Without 5,8% 23,3%
Precipitating
factors / 
associated
disease
% with
allele
C282Y
p-value
% with
allele
H63D
p-value
TABLE 5: Association of precipitating factors 
and associated diseases with presence of 
C282Y and H63D alleles 
Parameters Nr. With Nr. Without p-value
HCV HCV
Serum Iron x UNL 18 0.93 ± 0.33 30 1.02 ± 0.32 0.463
Ferritin x UNL 18 1.94 ± 1.33 29 2.11 ± 1.33 0.702
Transferrin 17 46.28 ± 17.28 28 54.77 ± 17.71 0.058
saturation (Tsat) %
Serum AST x UNL 20 2.57 ± 1.43 32 1.73 ± 0.82 0.034
Serum ALT x UNL 20 2.52 ± 1.46 32 1.81 ± 1.03 0.032
Serum GGT x UNL 20 4.12 ± 2.14 32 2.91 ± 2.91 0.015
TABLE 6: Comparison between biochemical parameters
(iron profile and liver enzymes) of patients with and
without hepatitis C (HCV) associated to porphyria
cutanea tarda
Note: Nr. = Number of patients; UNL = Upper normal limit; ALT:
Alanine transaminase; AST: aspartate transaminase and GGT: gamma-
glutamyl transpeptidase.
Genotype N % Nr Serum Iron Nr Ferritin Nr Tsat (%) Nr Serum AST Nr Serum ALT Nr Serum GGT 
x UNL x UNL x  UNL x UNL x UNL
C282Y/WT 6 10 6 0.93 ± 0.38 6 2.25 ± 0.95 6 52.68 ± 19.41 6 2.61 ± 1.49 6 2.84 ± 1.30 6 4.55 ± 3.41
C282Y/C282Y 1 1.7 1 1.13 1 1.45 1 89 1 0.44 1 0.45 1 0.86
H63D/WT 21 35 17 1.05 ± 0.39 17 1.94 ± 1.26 16 51.48 ± 20.24 20 2.15 ± 1.24 20 2.13 ± 1.21 19 4.05 ± 3.18
H63D/H63D 5 8.3 5 1.12 ± 0.09 5 2.15 ± 1.21 5 63.14 ± 19.32 5 1.93 ± 0.98 5 1.61 ± 0.94 5 2.06 ± 0.56
C282Y/H63D 2 3.3 2 1.25 ± 0.01 2 3.17 ± 1.53 2 70.61 ± 10.76 2 1.65 ± 0.83 2 2.79 ± 1.98 2 2.29 ± 2.8
WT/WT 25 41,7 23 0.89 ± 0.25 23 2.10 ± 1.62 22 46.53 ± 13.28 25 1.93 ± 0.96 25 1.96 ± 1.12 25 3.60 ± 2.81
TABLE 7: Iron profile (serum iron, ferritin, transferrin saturation) and liver enzymes (AST, ALT and GGT) 
according to HFE genotype of patient (mean ± standard deviation) in 60 patients 
Note: Nr. = Number of tested patients; % of patients; UNL: upper normal limit; Tsat = transferrin saturation; UNL serum iron: 158µg/dL (male) and
145 µg/dL (female); UNL ferritin: 400 ng/dL (male) and 150µg/dL (female); normal Tsat = 20 a 40%. Due to UNL differences between males and
females, we have described how many times the value was above UNL
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patients. We would expect a greater increase of ferritin
in patients with HCV; probably what is interfering in
this finding is the fact that in the group without HCV,
there are four HIV-positive patients and four patients
with HFE mutations, which also contributed to
increased ferritin levels. 
Association with HIV occurred in nine patients
(15.3%); the diagnosis was prior to PCT in six cases
and simultaneous in three cases; therefore, it is always
recommended to investigate HIV in these patients. As
has already been mentioned in literature, it cannot be
concluded that HIV alone contributes to the onset of
PCT, since all patients were associated with alco-
holism and five also presented HCV.41
The increased incidence in females can be
attributed to estrogen intake and increased consump-
tion of alcohol by females in recent decades. Among
the 16 females, estrogens have an important role in
eight (50%), and in 25% this was the only precipitating
factor - similar to other studies, in which estrogen
intake was the only triggering factor in more than 25%
of females with PCT.39 Three females had family histo-
ry of PCT, which reinforces the idea that estrogen
would act by inhibiting UROD, which genetically is
already diminished.3
PCT family history was present in 25% of
patients, but it was not possible to verify UROD ery-
throcyte activity or UROD gene mutations, prevent-
ing distinction between familial and sporadic PCT.
This frequency is similar to that found in other stud-
ies, ranging from 20 to 29% in different populations of
North America and Europe.4,39 Bulaj et al. reported that
inherited deficiency of UROD does not change demo-
graphic and clinical features of PCT, i.e., if the same
precipitating factors (excess iron, alcohol, HCV and
estrogens) contributed to clinical expression of both
types of PCT (familial or sporadic), for it is unlikely
that this has affected our results.39
PCT is an iron-dependent disease in which iron
overload is present in 60% to 70% of patients.34 In PCT,
transferrin saturation and ferritin are similarly
increased in patients with or without HFE mutations.22
As iron always has a changed profile in patients with
PCT, a research of mutations is important to identify
individuals at risk for developing iron overload.39
Brazilian population shows a high rate of ethnic
miscegenation: the population is composed mainly of
European descendants originating from Italy, Spain
and Portugal, Afro-descendants (primarily from
Angola, Congo and Mozambique) and native Indians;
in addition, Brazil also received immigrants from
Germany, Japan and the Middle East.42 There are sev-
eral studies reporting C282Y and H62D allele frequen-
cies in the normal Brazilian population.36,42,43 C282Y
mutation prevalence among healthy individuals
serum iron and ferritin levels were higher in patients
who were compound heterozygotes (C282Y/H63D)
in relation to other genotypes. Transferrin saturation
was higher in patients homozygous for C282Y (Tsat =
89%), followed by compound heterozygous
(Tsat=70.61±10.76%) and homozygous for H63D
(63.14 ± 19.32%). No difference was noted between
genotypes in relation to liver enzymes. 
DISCUSSION 
Apparently an unexplained interaction
between genetic and environmental factors is neces-
sary for the PCT phenotypic expression in most
cases.11 Most PCT patients presented multiple precipi-
tating factors, of which the most common combina-
tion is between alcohol and HCV in 80% of males; in
females, 40% have current estrogen intake as an isolat-
ed precipitating factor.11 In this study, the majority
(63%) presented two or more coexisting precipitating
factors. Chronic alcoholism was the most frequent
(71.7%) precipitating factor. Alcoholism is a long-rec-
ognized important precipitating factor in PCT; it acts
in synergy with other factors in predisposed individ-
uals.38 Some authors suggest that chronic alcoholism
may be associated with inheritance of HFE mutations,
since C282Y mutation is dominant in countries where
alcohol consumption is the most common PCT precip-
itating factor.35 However, in our study, no association
existed between alcoholism and presence of any of the
alleles; there is a greater proportion of patients with
C282Y and H63D alleles among non-drinkers, but this
difference did not have statistical significance. 
In literature, anti-HCV antibody prevalence
ranges from 8 to 91% and is related to the endemicity
of HCV in the population.1,39 In this study, positive
anti-HCV was 41.7% and the majority (84%) present-
ed association with alcoholism. Most of our patients
(60%) were diagnosed for HCV infection after the
emergence of PCT, hence the need to investigate HCV
in these patients. Chronic alcoholism places the
patient at risk of developing PCT, regardless of pres-
ence or absence of HCV. It is suggested that increasing
HCV prevalence can be related to increased alcohol
consumption, due to the fact that positivity for anti-
HCV has been reported in up to 25% chronic drinker
patients.40 However, our study has not demonstrated
association of HCV with alcoholism. This study has
also not observed a significant association of HCV
with other precipitating factors (estrogen intake, HIV
or presence of at least one HFE mutation allele).
Evidently, certain individuals are predisposed to
develop UROD deficiency, for the majority of individ-
uals suffering from hepatitis C does not develop PCT.9
Liver enzymes were higher in the HCV group; howev-
er, serum iron and ferritin levels were lower in these
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(C282Y allele carrier frequency: 2.7 to 4.9%) is lower
than the observed among Europeans. In relation to
H63D mutation, a high prevalence exists among
healthy Brazilians (frequency of allele holders: 21.6%
to 39.7%); similar to that observed in White
Europeans, particularly among Italians. In this study,
a previous study by Pereira et al. , also held at this
Hospital (HCFMUSP) with 395 blood donors in 200l,
was used as control group.36 Variable frequencies of
C282Y and H63D alleles between different ethnic
groups occur in Brazil (Euro-Brazilians, Afro-descen-
dants and a mixture of ethnicities); frequency was
high among Euro-Brazilians, which supports the the-
ory of European origin of mutations.36 As to total fre-
quency of alleles in the normal population, we
encountered 14/790 = 1.77% CI [95%] = [0.97%; 2.96%]
for C282Y and 111/790 = 14,05% CI [95%] = [11.7%;
16.67%] for H63D.36 These results are very close to
those found in Italian and Portuguese populations,
which can be explained by the immigration observed
in São Paulo.19,43,44
The prevalence of HH in Brazilian population is
unknown. In Brazil, approximately one third of
patients with HH classical phenotype do not present
HFE mutations or other mutations associated with
disease, suggesting that there may be other unknown
mutations in the HFE gene or other genes involved in
iron homeostasis.30 These findings also match reports
from Italy, where approximately one third of patients
with HH do no present C282Y or H63D mutations.44
The difference in genotypes found in Brazil may be
explained by Brazilian racial miscegenation, with pre-
dominant migration from Southern Europe, where
mutations are less frequent, and a high influence of
African descent and Native Americans, whose popu-
lations have a low frequency of these mutations.43 As
in Brazilian population prevalence of S65C mutation
is low in the healthy population and this mutation
was not found among patients with iron overload, we
do not consider research of these mutations relevant
in patients of this study.30,43
Only one Brazilian study researched the associ-
ation of HFE mutation (C282Y and H63D) in PCT. 23 In
23 PCT patients, four patients presented C282Y muta-
tion (27.4%) and seven patients presented H63D
mutation (30.4%). The majority was heterozygous for
the mutation; only one was homozygous for H63D
mutation; one was compound heterozygous
(C282Y/H63D) and none homozygous for C282Y. In
the control group, 278 individuals were observed:
C282Y mutation was found in 4% and H63D mutation
in 31.1%. Comparing both groups, there was a signifi-
cant statistical difference between the two groups for
C282Y mutation (OR=5.1, 95% IC 1.5-17.6, p = 0.02),
but it was not the case for H63D (OR=1, 95% IC 0.4-
2.4, p = 1).23 In our study, the frequency of two muta-
tions was significantly higher in PCT patients in rela-
tion to control population for C282Y (p=0.0001) and
for H63D (p= 0.0004). We may conclude that HFE
mutations increase the susceptibility of individuals to
PCT; iron buildup precipitates manifestation of PCT
in individuals already predisposed to the disease. The
association of iron and chronic hepatitis C led to
investigation of HFE mutations as a contributing fac-
tor for progression of liver disease, but the results are
conflicting. Some researches report the association of
HFE mutations with severe liver disease, while others
have not found this association.8 The HCV infection
and the C282Y mutation are independent precipitat-
ing factors, for in a study of Stuart et al. all HCV
patients were homozygous for the wild type22 and in a
study of Toll et al. C282Y prevalence was higher
among patients without HCV.45 In our study, no asso-
ciation was observed between precipitating factors
(HCV, HIV, alcoholism and estrogen) and presence of
C282Y and H63D alleles. Patients with a PCT family
history tended to have an increased frequency of
C282Y and H53D alleles, but it was not statistically
significant (p=0.1440 and p=0.2514, respectively);
allele inheritance may contribute in part with PCT
family history. There has been a tendency to an
increase of H63D allele among patients with diabetes
mellitus (p=0.0834), but not for C282Y alleles. This
finding may be due to the fact of high prevalence of
H63D mutation, present in the normal Brazilian pop-
ulation.
HH presents few specific signs or symptoms to
alert the physician. The symptoms are nonspecific
(e.g. arthralgia, weakness and fatigue) and do not help
when there is suspicion of HH.46 Symptoms usually
develop in patients over 40 years of age, at a time
when iron deposition in organs may have caused irre-
versible damage in tissues, such as cirrhosis, hepato-
cellular carcinoma, arthritis, hypogonadism, diabetes
mellitus and cardiomyopathy.47 One of the patients in
this study had prior clinical diagnosis of HH as single
precipitating factor of PCT. This patient was Oriental
and heterozygous for H63D; probably other unknown
mutations related to HH were contributing to the out-
break of PCT in this case. Neither the homozygous
C282Y patient nor his compound heterozygous sister
presented any other precipitating factors, except HFE
mutations and family history. These three patients
indicate that HFE mutations or clinical manifestation
of hemochromatosis may contribute to the triggering
of PCT, regardless of the presence of other precipitat-
ing factors.
The phenotypic expression of HH is higher in
homozygous patients for C282Y and in compound
heterozygotes.11 Through discovery of the HFE gene, it
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was possible to identify ‘potential’ risk of developing
iron overload, for not all C282Y homozygotes will
develop iron overload or HH, and it is not possible to
predict the degree of phenotypic expression. In our
study, it was observed that serum iron and ferritin lev-
els were higher in compound heterozygous patients
(C282Y/H63D) in comparison to other genotypes, and
there was no difference in liver enzymes between
genotypes. As for transferrin saturation, it was higher
in homozygous C282Y patients (Tsat = 89%), followed
by compound heterozygous (Tsat = 70.61±10.76%) and
H63D homozygotes (Tsat = 63.14%), indicating that
this parameter may be important when suspicion of
association with HFE mutations arises regarding PCT
patients. HH is suspected when transferrin saturation
is >50% in premenopausal females and >60% in males
or postmenopausal females but the elevation of Tsat is
not specific to HH.48 Elevation of Tsat is the first man-
ifestation of HH and may be high in young individu-
als, who still possess normal ferritin.49 In order to
quantify iron overload in HH, we usually use plasma
ferritin, but this interpretation is distorted in PCT and
in several other infectious and inflammatory diseases
(acute phase reactant), e.g. in alcoholic hepatitis, non-
alcoholic steatohepatitis, hepatitis C, rheumatoid
arthritis and neoplastic diseases such as lymphoma.49
In patients with HFE mutations or clinical manifesta-
tion of HH, which present factors that interfere with
plasma ferritin, we usually suggest use of magnetic
resonance imaging (MRI) of the liver in order to quan-
tify liver iron concentration, a noninvasive method
with a high degree of sensitivity and preciseness in
order to measure iron concentration, as well as pro-
viding information about degree of fibrosis.50 One
should always monitor iron levels in PCT patients
(regardless of presence of HFE mutation), even when
they are in a biochemical remission of disease, for
these patients may present unknown factors that lead
to an increase in iron level and subsequently lead to
PCT recurrence. 
CONCLUSION
Alcoholism, hepatitis C and estrogen intake
(females) are precipitating factors, prevalent in PCT
Brazilian population, but HH alone may also con-
tribute to the onset of PCT, which makes research of
HFE mutations or HH phenotypes in these patients
important .
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